Acupuncture plus immunotherapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding electroacupuncture to a PD-1 inhibitor (a type of immunotherapy) can help people with advanced non-small cell lung cancer who have limited activity levels. It may improve treatment response and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IIIB or IV non-small cell lung cancer (confirmed by biopsy or lab test).
- Your cancer does not have certain gene mutations (like EGFR or ALK) that are treatable with targeted therapy.
- Your ECOG performance status is 2, meaning you are up and about more than 50% of the day but may need some help.
- Your tumor has at least 1% PD-L1 expression (a marker for immunotherapy benefit).
- Your doctor expects you to live at least 3 more months.
- You agree to follow the study plan and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding electroacupuncture (a gentle, needle-based therapy) to a standard immunotherapy drug (PD-1 inhibitor) can help older adults with advanced lung cancer. It may improve treatment response and quality of life.
This trial explores whether adding electroacupuncture (a gentle needle treatment with mild electric pulses) to standard immunotherapy after lung cancer surgery can help prevent the cancer from coming back. It is designed for people with early-stage non-small cell lung cancer who have already had chemotherapy.
This study tests whether adding electro-acupuncture (a gentle type of acupuncture with mild electrical pulses) to standard first-line immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer. It aims to see if this combination improves quality of life and overall treatment outcomes.
This trial tests if adding electroacupuncture at a specific point (ST36, below the knee) to standard chemotherapy and immunotherapy can help people with lung cancer. It aims to improve treatment outcomes and quality of life.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests if adding acupuncture to standard immunotherapy and chemotherapy helps people with advanced lung cancer. It is for those who have not had treatment before and whose tumors have low PD-L1 levels.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.